Minghui Pharmaceutical
PrivateLast Round
pre_ipo
Aug 7, 2025
Est. Valuation
$545M
Total Funding Raised
$11.13M
Company Overview
Minghui Pharmaceutical operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a pre_ipo round in August 2025.
Minghui Pharmaceutical is a biopharmaceutical company that develops transformative medicines for patients with oncology and autoimmune conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Minghui Pharmaceutical Comparables
Compare Minghui Pharmaceutical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TechnoDerma Medicines Inc. | 75% | |
| InnoCare Pharma Limited | 72% | |
| MediLink Therapeutics | 69% |
For institutional investors. Book with your work email.
Minghui Pharmaceutical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| pre_ipo | Aug 7, 2025 | ||||
| Seed | Apr 1, 2018 |
For institutional investors. Book with your work email.
Minghui Pharmaceutical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | pre_ipo |
| Boyuan Capital | VC Round |
| TF Capital | VC Round, pre_ipo |
| OrbiMed | pre_ipo |
| 5Y Capital | pre_ipo |
| New Day Venture Capital | pre_ipo |
| Qiming Venture Partners | pre_ipo |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 7, 2025
$131M round led by OrbiMed and Qiming Venture Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyNov 4, 2026
Minghui Pharmaceutical Ltd. grants ASKA Pharmaceutical Co., Ltd. exclusive rights to develop, seek regulatory approval for, and commercialize MHB018A in Japan under an agreement announced on Nov 4th '26.
- partners_withNov 4, 2026
Minghui Pharmaceutical Ltd. partners with ASKA Pharmaceutical Co., Ltd. in Japan, granting ASKA Pharmaceutical Co., Ltd. exclusive rights to develop, seek regulatory approval for, and commercialize MHB018A while Minghui Pharmaceutical Ltd. retains rights outside Japan and leads global development, under an agreement dated Nov 4th '26.
- is_developingNov 4, 2026
On Nov 4th '26 in Japan, Minghui Pharmaceutical Ltd. develops MHB018A, a subcutaneous antibody targeting IGF-1R for thyroid eye disease, through a Phase III program while ASKA Pharmaceutical holds exclusive Japanese rights to develop, seek approval for, and commercialize it.
For institutional investors. Book with your work email.
Minghui Pharmaceutical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Minghui Pharmaceutical's valuation, stock price, and market status.
Is Minghui Pharmaceutical a public or private company?
Minghui Pharmaceutical is a private company.
What is the current stock price of Minghui Pharmaceutical?
Minghui Pharmaceutical is a private company, so its shares have no public market price. Caplight tracks Minghui Pharmaceutical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Minghui Pharmaceutical worth (valuation)?
Minghui Pharmaceutical's valuation is estimated at $545.0M based on funding round data.
Can I buy Minghui Pharmaceutical stock?
Minghui Pharmaceutical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Minghui Pharmaceutical's last funding round?
Minghui Pharmaceutical's most recent funding round was pre_ipo on August 7, 2025.
Who are the main investors in Minghui Pharmaceutical?
Key investors in Minghui Pharmaceutical include OrbiMed, Qiming Venture Partners.
Will Minghui Pharmaceutical IPO soon?
No public IPO plans have been announced for Minghui Pharmaceutical.
How can I track Minghui Pharmaceutical secondary market activity?
Caplight tracks bids, offers, and trades in Minghui Pharmaceutical's shares on secondary markets.